Loading...

Brentuximab Vedotin in CD30+ Lymphomas

Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin’s lymphoma (cHL) and anaplastic la...

Full description

Saved in:
Bibliographic Details
Main Authors: Perini, Guilherme Fleury, Pro, Barbara
Format: Artigo
Language:Inglês
Published: Springer Healthcare 2013
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3873074/
https://ncbi.nlm.nih.gov/pubmed/24392301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13554-013-0008-7
Tags: Add Tag
No Tags, Be the first to tag this record!